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Abstract
Background: Suppressor of cytokine signaling (SOCS) proteins comprise a protein family, which
has initially been described as STAT induced inhibitors of the Jak/Stat pathway. Recent in vivo and
in vitro studies suggest that SOCS proteins are also implicated in cancer. The STAT5 induced IGF-
I acts as an endocrine and para/autocrine growth and differentiation factor in mammary gland
development. Whereas high levels of circulating IGF-I have been associated with increased cancer
risk, the role of autocrine acting IGF-I is less clear. The present study is aimed to elucidate the
clinicopathological features associated with SOCS1, SOCS2, SOCS3, CIS and IGF-I expression in
breast cancer.
Methods: We determined the mRNA expression levels of SOCS1, SOCS2, SOCS3, CIS and IGF-
I in 89 primary breast cancers by reverse transcriptase PCR. SOCS2 protein expression was further
evaluated by immuno-blot and immunohistochemistry.
Results: SOCS2 expression inversely correlated with histopathological grade and ER positive
tumors exhibited higher SOCS2 levels. Patients with high SOCS2 expression lived significantly
longer (108.7 vs. 77.7 months; P = 0.015) and high SOCS2 expression proved to be an independent
predictor for good prognosis (HR = 0.45, 95% CI 0.23 – 0.91, P = 0.026). In analogy to SOCS2, high
IGF-I expression was an independent predictor for good prognosis in the entire patient cohort. In
the subgroup of patients with lymph-node negative disease, high IGF-I was a strong predictor for
favorable outcome in terms of overall survival and relapse free survival (HR = 0.075, 95% CI 0.014
– 0.388, P = 0.002).
Conclusion: This is the first report on the favorable prognostic value of high SOCS2 expression
in primary mammary carcinomas. Furthermore a strong association of high IGF-I expression levels
with good prognosis was observed especially in lymph-node negative patients. Our results suggest
that high expression of the STAT5 target genes SOCS2 and IGF-I is a feature of differentiated and
less malignant tumors.
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Background
SOCS proteins comprise a family of eight members
(SOCS1-7 and CIS), which have initially been described
as STAT induced STAT inhibitors or more generally as neg-
ative regulators of cytokine signaling via the Jak/Stat path-
way. Their ability to modulate signal transduction is based
on two functional domains, an SH2 domain, which binds
to phosphorylated tyrosine residues and a SOCS box,
which serves as a recruiting site for ubiquitin ligases [1].
Recent reports, showing the interaction of SOCS proteins
with various other signaling molecules like p65, FAK, c-
kit, IRS1/2 and vav, indicate a more general role of SOCSs
proteins in the maintenance of cellular homeostasis [2-6].
Tumors often exhibit alterations in SOCS protein expres-
sion: CpG island methylation of SOCS gene loci, and con-
sequently, inhibition of SOCS expression was observed in
a variety of solid tumors and hematological malignancies
[7-13]. On the other hand, forced overexpression of
SOCS1 and SOCS2 results in diminished transformation
and decreased metastatic potential [8,14]. Taken together,
these in vivo and in vitro data support the role of SOCS
proteins as tumor suppressors. To evaluate the potential
significance of SOCS expression in mammary carcinoma
for prognosis and its association with clinicopathological
characteristics we have investigated the mRNA levels of
SOCS1, SOCS2, SOCS3 and CIS in a representative collec-
tion of primary breast cancers specimens. Since our study
revealed SOCS2 expression as a predictor for prognosis,
and growth hormone is a major inducer of SOCS2, we
became interested in the expression of the growth hor-
mone regulated gene IGF-I. IGF-I is a growth and differen-
tiation factor, which acts in an endocrine – via the
classical hypothalamus/pituitary/liver axis – and in a
paracrine/autocrine manner [15]. In the normal mam-
mary gland, IGF-I is required for structural development,
promoting ductal growth and differentiation [16].
Whereas epidemiological data indicate that high levels of
circulating serum IGF-I are associated with an increased
risk for the development of solid tumors including breast
cancer, little is known on the role of autocrine produced
IGF-I [15,17]. We therefore evaluated the expression levels
of locally produced IGF-I in the tumor. Interestingly, high
IGF-I mRNA levels were associated with good prognosis,
suggesting that secretion of IGF-I by the tumor is a prop-
erty of a less malignant and more differentiated tumor.
Methods
Patients and tumor specimens
Tissue samples from patients treated at the Department of
Obstetrics and Gynecology, Innsbruck Medical Univer-
sity, Austria (n = 52, referred to as A), and the Centre
Oscar Lambert Anticancer Center of the North of France,
Lille (n = 37, referred to as B) for primary breast cancer
were included in this retrospective study. Since the initial
results obtained in patient sample collection A suggested
a prognostic significance of SOCS2 and IGF-I, we further
sought to test the variables in another independent
patient cohort (collection B) to overcome the potential
problem of selection bias and to increase the statistical
power. The clinicopathological characteristics of the
entire cohort (n = 89) are shown in Table 1. Median age
was 62.2 years (range, 35 to 81) and median follow up
time was 6.8 years (range, 0.6 to 11.8). During follow up
40 patients relapsed and 37 died. Specimens with a tumor
content of more than 90% were snap frozen, ground to
powder under liquid nitrogen and stored at -80°C until
further analysis. Estrogen and progesterone receptor status
was assessed by ligand binding assay as described previ-
ously [18].
RNA preparation and RT-PCR
RNA was extracted from tissue powder as described previ-
ously [19]. Integrity of prepared RNA was evaluated by
determination of ethidiumbromide-stained 18S and 28S-
Table 1: Clinical characteristics of patients
Feature
Total Number 89
Age at diagnosis
Median 62.2
Range 35 – 81
Histotype
Infiltrating ductal carcinoma 60 (67)
Infiltrating lobular carcinoma 10 (11)
Others 19 (21)
Histopathological grade
I 35 (39)
II 24 (27)
III 24 (27)
Not classified 6 (7)
Lymph-node status
Positive 48 (54)
Negative 38 (43)
Unknown 3 (3)
Estrogen receptor
positive 68 (76.4)
negative 21 (23.6)
Progesterone receptor
positive 64 (71.9)
negative 25 (28.1)
Follow-up
Median 6.8
Range 0.6 – 11.8
Numbers in parentheses are percentagesBMC Cancer 2007, 7:136 http://www.biomedcentral.com/1471-2407/7/136
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ribosomal RNA bands in an agarose gel. 0.5 µg of total
RNA were reverse transcribed with Superscript III (Invitro-
gen, Carlsbad, CA, USA) according to manufacturer's
instructions. Primer and Taq-Man probe oligonucleotide
sequences for SOCS1, SOCS2, SOCS3, CIS, IGF-I and
TATA box-binding protein are shown in Table 2. All PCR
reactions were carried out on an ABI Prism thermocycler
(PerkinElmer, Inc., Wellesley, MA, USA) at 95°C for 10
min followed by 40 cycles of 95°C for 15 s and 60°C for
30 s in a 25 µl volume containing 1× BioTherm Star™PCR
Buffer (GeneCraft, Lüdinghausen, Germany), 5 mM
MgCl2, 1U Taq-Polymerase BioThermStar™ (GeneCraft),
300 µM dATP, 300 µM dGTP, 300 µM dCTP, 300 µM
dTTP, 200 nM forward primer, 200 nM reverse primer,
100 nM of TaqMan probe, 300 nM reference dye (Strata-
gene, La Jolla, CA), and 2 µl of cDNA. To control for vari-
ations in RNA quality and quantity, expression of the gene
of interest was normalized to the expression of TATA box
binding protein (TBP) [20]. Each reaction included a
standard-control sample and a non template control. To
test for amplification efficiency, series dilutions of the
control samples were analyzed. Representative amplifica-
tion plots are shown [see Additional file 1]. Relative
mRNA expression levels were calculated according to the
formula: 2-∆∆CT, where ∆CTsample was defined as CTgene of
interest – CTTBP and ∆∆CT as ∆CTsample – ∆CTnormalization sam-
ple.
Immunohistochemistry
COS 7 monkey kidney cells were grown in DMEM con-
taining 10% FCS at 37°C in 5% CO2/95% air. Cells were
transiently transfected with a myc tagged SOCS2 expres-
sion plasmid [21] using TransFast™ transfection reagent
(Promega, Madison, WI). Thirty six hours after transfec-
tion cells were trypsinized and centrifuged at 1000 g for
10 min. The cell pellet was then resuspended in a 4% low-
melting agarose (United States Biochemical, Cleveland,
Ohio) PBS solution. After hardening of the agarose, the
gel pellet was incubated overnight in 4% paraformalde-
hyde for 12 h, paraffin embedded and processed for
immunohistochemistry with an anti-myc or anti-SOCS2
antibody to assess the specificity of the antibody against
SOCS2.
Immunohistochemistry was performed a described previ-
ously [22]. Primary anti-SOCS2 antibody (FA1016,
Fusion Antibodies Ltd, Belfast, Ireland) was applied at
1:50 dilution for 30 min at room temperature. Eight cases
for which both paraffin embedded and frozen tissue were
available were investigated.
Western Blot
Whole cell extracts from pulverized tumour and normal
adjacent tissue were prepared as described previously
[18]. Membranes were then probed with an anti-SOCS2
rabbit polyclonal antibody (FA1016, Fusion Antibodies
Ltd, Belfast, Ireland) at 1:500, mouse monoclonal anti-
actin (C-2, Santa Cruz Biotechnology, Santa Cruz, CA)
1:200 and further incubated in 1:5000 anti-rabbit IR 800
secondary antibody (Rockland, PA) and 1:5000 anti-
mouse IR 680 secondary antibody (Molecular Probes, Lei-
den, Netherlands), respectively. Immunoreactive bands
were detected using a LICOR Odyssey Infrared Imager (LI-
COR, Biosciences, Lincoln, NB). To test for antibody spe-
cificity, lysates from COS7 cells transiently transfected
with a myc-tagged SOCS2 plasmid were probed with an
anti-c-myc antibody (9E10, Santa Cruz Biotechnology,
Santa Cruz) and anti-SOCS2 antibodies. Both antibodies
recognized the recombinant protein and showed an
immunoreactive band at the estimated molecular weight.
Statistical analysis
Correlations between parameters were assessed according
to the Spearman nonparametric test. Differences in the
distributions of SOCS2 and IGF-I between tumor and nor-
Table 2: Primers and Probes for real-time PCR
Gene 
Symbol
Sequence
SOCS1 Forward 5'-TTTTCGCCCTTAGCGTGAAG-3'
Reverse 5'-CATCCAGGTGAAAGCGGC-3'
Taqman probe 5'FAM-
CCTCGGGACCCACGAGCATCC-
3'TAM
SOSC2 Forward 5'-CAGATGTGCAAGGATAAGCGG-3'
Reverse 5'-CAGATAAAGGTGAACAGTGCCG-3'
Taqman probe 5'FAM-
CAGGTCCAGAAGCCCCCCGG-3'TAM
SOCS3 Forward 5'-TGATCCGCGACAGCTCG-3'
Reverse 5'-TCCCAGACTGGGTCTTGACG-3'
Taqman probe 5'FAM-
CCAGCGCCACTTCTTCACGCTCA-
3'TAM
CIS Forward 5'-TCCAACTGCTTGTCCAGGC-3'
Reverse 5'-GTGCTGCACAAGGCTGACC-3'
Taqman probe 5'FAM-
ACGCATCCTGGCCTTTCCGGA-
3'TAM
TBP Forward 5'-CACGAACCACGGCACTGATT-3'
Reverse 5'-TTTTCTTGCTGCCAGTCTGGAC-3'
Taqman probe 5'FAM-
TCTTCACTCTTGGCTCCTGTGCACA-
3'TAM
IGF-I Forward 5'-TCAGCTCGCTCTGTCCGTG-3'
Reverse 5'-TGACTCCCTCTACTTGCGTT-3'
Taqman probe 5'FAM-
TGCCCAAGACCCAGAAGGAAGTACA
TTTG-3'TAMBMC Cancer 2007, 7:136 http://www.biomedcentral.com/1471-2407/7/136
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mal adjacent tissue were compared using Mann-Whitney
test. The Kruskal-Wallis one-way ANOVA was used to test
for differences in SOCS and IGF expression levels between
histopathological grade groups. Overall survival and
relapse free survival between the mRNA expression cate-
gories were compared using Kaplan-Meier plots and the
log-rank test. The median was determined as an optimal
cut-off value to separate the low and high expression cat-
egories. A COX proportional hazards regression model
was used to estimate the hazard ratio (HR) associated with
SOCS1, SOCS2, IGF-I expression. The final multivariate
model included lymph node-status, estrogen and proges-
terone receptor status and histopathological grade. All sta-
tistical analysis were performed using SPSS 11.0 for Mac
OS (SPSS, Inc., Chicago, IL). A P-value < 0.05 was consid-
ered statistically significant.
Results
SOCS and IGF-I mRNA and clinicopathological features
The mRNA content of SOCS1, SOCS2 and IGF-I was
assessed in 89 primary breast cancer samples, and of
SOCS3 and CIS in 64 samples. The patient characteristics
are shown in Table 1. In all breast tumors transcripts of
the investigated genes were detectable and quantifiable.
SOCS1
SOCS1 expression was negatively associated with ER and
PR levels (r = -0.224, P = 0.037; and r = -0.239, P = 0.026,
respectively). The group of patients with low SOCS1
expression exhibited longer overall survival (100.3 versus
84.7 months). This association of low SOCS1 expression
and good prognosis reached border-line statistical signifi-
cance (P = 0.07) and is in line with recent findings from
our group, showing that activation of STAT1 is an indica-
tor for favorable outcomes in mammary carcinoma, since
SOCS1 is a negative regulator of STAT1 activation [18].
SOCS2
A statistical highly significant correlation was observed
between SOCS2 expression and pathological grade (r = -
0.306, P = 0.005). There, tumors with low histopatholog-
ical grade had higher SOCS2 mRNA content. This is in
agreement with recent findings showing that high SOCS2
protein expression is associated with lower pathological
grade and lower cell proliferation indices [23]. Further-
more, tumors with high SOCS2 content tended to be
estrogen (r = 0.257, P = 0.015) and progesterone receptor
positive (r = 0.246, P = 0.02) and significantly higher
SOCS2 levels were observed in the subgroup of ER posi-
tive tumors (P = 0.04) indicating a general tendency for
more differentiated tumors to have high SOCS2 expres-
sion. It was of particular interest, that patients with high
SOCS2 expression lived significantly longer (108.7 vs.
77.7 months; P = 0.015; Figure 1). The difference in dis-
ease free survival was in the same direction but did not
reach statistical significance (91.9 versus 74.3 months; P =
0.22). After adjusting for tumor grade, lymph node, ER
and PR status high SOCS2 expression remained an inde-
pendent predictor for good prognosis (Table 3). This is
the first evidence for a prognostic relevance of SOCS
expression in breast cancer.
SOCS3 & CIS
CIS correlated with estrogen receptor (r = 0.273, P =
0.029), and progesterone receptor status (r = 0.272, P =
0.03). For neither CIS nor SOCS3 there was a statistically
significant association between mRNA expression levels
and overall or relapse free survival. We observe a positive
correlation of CIS and SOCS2 mRNA levels (r = 0.25, P =
0.047). This is in agreement with the notion that both CIS
and SOCS2 have been described as STAT5 target genes
[24].
IGF-I
We included IGF-I as another STAT5 regulated gene in our
study. Tumors with high IGF-I expression tended to be ER
and PR positive (r = 0.24, P = 0.028; r = 0.27, P = 0.011).
Furthermore, a strong positive correlation between high
SOCS2 and high IGF-I expression was observed (r = 0.4, P
< 0.001). In analogy to SOCS2, IGF-I levels above the
median were associated with significantly longer overall
survival (76.3 versus 110.5 months; P = 0.01; Figure 1),
and showed a borderline significant association to longer
disease free survival (70.9 versus 96.1 months; P = 0.082).
In a multivariate COX regression model we were able to
show the prognostic relevance of high IGF-I expression
(Table 3). This is in line with previously reported data
[25]. Subgroup analysis in 30 patients who had both, high
SOCS2 and high IGF-I expression did only show a minor
advantage for the combination of the two markers in
terms of predicting overall survival (118.5 versus 79.55
Kaplan-Meier curve assessment of risk of death in a cohort of  89 patients with invasive breast cancer Figure 1
Kaplan-Meier curve assessment of risk of death in a cohort of 
89 patients with invasive breast cancer. Overall survival is 
shown for patients with high and low SOCS2 and IGF-I 
expression, respectively. The median was taken as a cut-off. P 
values were determined using the log-rank test.
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months; P = 0.005). When we restricted our analysis to
lymph-node negative patients, who are known to have
better prognosis than lymph-node positive patients [26],
we observed an even more pronounced difference in over-
all survival and relapse-free survival (Figure 2): There, low
IGF-I expression defined a subgroup of patients who were
at very high risk for recurrence. High IGF-I expression,
conversely was associated with a significantly decreased
risk for recurrence (HR = 0.075, 95% CI 0.014 – 0.388, P
= 0.002).
SOCS2 and IGF-I in tumor and normal adjacent tissue
We further compared the mRNA expression of SOCS2 and
IGF-I in primary breast carcinomas (CA) and the corre-
sponding normal adjacent tissue (TA) in a set of seven
tumors. The mean SOCS2 and IGF-I expression levels
were 9.4 and 8.4 fold higher, respectively, in TA than in
CA (Figure 3A). SOCS2 was significantly correlated with
IGF-I expression (r = 0.736, P = 0.003). SOCS2 mRNA
data were further corroborated by Western blot analysis
(Figure 3B) with an antibody evaluated for its specificity
by experiments with cells expressing recombinant SOCS2
protein (see Methods section). The same antibody was
also found to be suitable for immunohistochemistry.
There, in primary mammary carcinoma immunohisto-
chemical staining of SOCS2 correlated with SOCS2
mRNA expression. In tumors with high SOCS2 mRNA lev-
els, epithelial tumor cells showed cytoplasmatic staining
for SOCS2 (Figure 4). In normal breast tissue, ducts, and
to a lesser extent, stroma cells exhibited staining for
SOCS2 (not shown). Although SOCS2 protein content
was not measured in all samples of our tumor collection,
the high correlation between SOCS2 protein and mRNA
expression in 14 samples investigated by westernblot
analysis and in 8 samples by immunohistochemistry sug-
gests that SOCS2 mRNA levels, as determined by RT-PCR
are a suitable indicator for how much SOCS2 protein is
expressed.
Discussion
Several recent reports have investigated the role of SOCS
proteins in the oncogenesis of various solid tumors and
hematological malignancies [7-13] indicating a central
role of SOCS proteins in the regulation of cellular growth
and differentiation. SOCS promoter methylation and
consequent gene silencing has been observed in hepato-
cellular carcinoma, lung cancer, head and neck cancer,
multiple myeloma and AML [9-13]. Conversely, restora-
Comparison of SOCS2 and IGF-I expression Figure 3
Comparison of SOCS2 and IGF-I expression. (A) Box blots 
with data from a set of seven tumors comparing the relative 
mRNA expression levels in tumor (CA) and normal adjacent 
tissue (TA). (B) SOCS2 protein and corresponding SOCS2 
mRNA expression in normal and cancerous tissue of two 
tumor specimens. SOCS2 protein expression was assessed 
by immuno-blot with an antibody directed against SOCS2. 
Actin was used as a loading control.
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Table 3: Multivariate Cox regression analysis for overall survival
Variable Hazard ratio 95% 
confidence 
interval
P
SOCS2
less than median 1.00 0.026
greater than median 0.453 0.23 – 0.91
IGF-I
less than median 1.00 0.017
greater than median 0.414 0.23 – 0.85
Kaplan-Meier curve assessment of risk of death and risk of  disease recurrence in 37 patients with lymph-node negative  disease Figure 2
Kaplan-Meier curve assessment of risk of death and risk of 
disease recurrence in 37 patients with lymph-node negative 
disease. Overall survival and relapse free survival (progres-
sion free survival) is shown for patients with high (17 pts.) 
and low (20 pts.) IGF-I expression.
Observation (years)
024 6 8 10 12
0
0.2
0.4
0.6
0.8
1
Observation (years)
024 6 8 10 12
0
0.2
0.4
0.6
0.8
1 IGF-I
High
Low
P = 0.005 P = 0.01
High
Low
IGF-I
O
v
e
r
a
l
l
 
s
u
r
v
i
v
a
l
P
r
o
g
r
e
s
s
i
o
n
 
f
r
e
e
 
s
u
r
v
i
v
a
lBMC Cancer 2007, 7:136 http://www.biomedcentral.com/1471-2407/7/136
Page 6 of 9
(page number not for citation purposes)
tion of SOCS protein expression resulted in induction of
apoptosis and suppression of growth. These findings sug-
gest an antioncogenic role of SOCS proteins.
However, little is known on the prognostic significance
and the association of SOCS expression with clinico-
pathological features. In this study, we therefore sought to
elucidate the relationship between pathological and clin-
ical parameters and the expression of the SOCS family
members SOCS1, SOCS2, SOCS3, and CIS in patients
with breast cancer by RT-PCR.
Our results showed that high SOCS2 expression is associ-
ated with increased overall survival and after adjusting for
age, lymph-node status, estrogen receptor status and
tumor grade, high SOCS2 expression remained an inde-
pendent predictor for good prognosis (Table 3). Farabe-
goli et al. recently provided first evidence that high SOCS2
protein expression is associated with lower pathological
grade and lower cell proliferation indices [23]. Together
with our findings of highly significant negative correlation
between SOCS2 expression and histopathological grade,
positive correlation with steroid receptors, which are
markers of differentiation, and the higher expression in
normal tumor adjacent tissue as compared to carcinoma
tissue, these results indicate that SOCS2 is a marker for
differentiated tumors. Similar to our observations in
breast cancer low SOCS2 expression in prostate cancer is
associated with an increased incidence of metastasis and
SOCS2 mRNA levels decrease during prostate cancer pro-
gression [27]. Furthermore, SOCS2 expression was found
to be down-regulated in pulmonary adenocarcinoma
[28]. The important role of SOCS2 as a regulator of
growth hormone signaling raises the intriguing question,
whether in mammary carcinoma, SOCS2 serves as an
essential regulator of cellular growth and tissue homeos-
tasis and its expression is required for the maintenance of
a more differentiated and less malignant phenotype.
However, Raccurt et al. described an increased expression
in cancerous ducts and reactive stroma as compared to
normal breast tissues by using in situ hybridization [29].
This result is not in agreement with our findings obtained
by RT-PCR, immuno-blotting and immunohistochemis-
try and might be due to the differences in the detection
methods.
The fact that SOCS2 has been described to be induced by
and to modulate the GH receptor/Jak/STAT pathway
prompted us to further investigate the expression of
another downstream target of the GH receptor, IGF-I
[30,31]. Similarly to our observations with SOCS2, high
IGF-I mRNA expression proved to be a predictor for good
prognosis (Figure 1 &2), and normal adjacent tissue was
characterized by increased IGF-I mRNA levels (Figure 3).
Our study confirms the results from a previous report
from a large sample collection in which patients with high
IGF-I expression tended to have a favorable prognosis
[25].
Mammary epithelial cell specific overexpression of IGF-I
which mimics autocrine IGF-I, increased the incidence of
mammary carcinomas in mice [32], whereas liver-specific
deletion of IGF-I, eliminating serum IGF-I, results in
reduced tumor development [33]. Several large epidemio-
logical studies highlighted this association also in
humans, revealing an increased risk for breast cancer espe-
cially in women with elevated serum levels of IGF-I before
the age of 50 [34]. Compiled evidence suggests that high
IGF-I renders cells susceptible to transformation by sec-
ondary events and thereby contributes to tumor progres-
sion [15]. We observed an increased expression of IGF-I in
Detection of SOCS2 in primary mammary carcinoma sam- ples by immunohistochemistry Figure 4
Detection of SOCS2 in primary mammary carcinoma sam-
ples by immunohistochemistry. Representative immunohisto-
chemical stainings of samples with low SOCS2 (A) and high 
SOCS2 (B) mRNA expression are shown. Note a strong 
cytoplasmatic epithelial staining for SOCS2 in tumors with 
high SOCS2 mRNA levels (B).
A
B BBMC Cancer 2007, 7:136 http://www.biomedcentral.com/1471-2407/7/136
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normal tumor adjacent tissue as compared to cancerous
tissue. This is in line with a previous reports comparing
IGF-I expression in large collections of normal mammary
glands and breast cancer specimens [25,35]. Differences
in IGF-I expression levels between normal and cancerous
tissue could partly be explained by differences in the pre-
vailing cell types. Several reports showed that IGF-I
expression is restricted to stroma cells in the mammary
gland [36]. High stroma content, frequently found in
highly differentiated tumors would therefore result in
higher IGF-I levels, which could explain the positive prog-
nostic value of high IGF-I expression. However, MCF7 and
T47D mammary carcinoma cells showed expression of
IGF-I (Haffner MC, Doppler W, unpublished observation)
indicating that also epithelia cells are capable of produc-
ing IGF-I.
Interestingly, we observed that high IGF-I expression is a
very potent predictor for good prognosis in patients with
lymph-node negative disease (Figure 2). Histological sta-
tus of the axillary lymph-nodes represents an important
prognostic factor. Patients with even a single lymph-node
metastasis have a poorer outcome than those with nega-
tive nodes and decision on systemic chemotherapy is
largely based on lymph-node status [26]. Risk stratifica-
tion in patients without lymph-node involvement is diffi-
cult. Hence markers predicting the outcome of patients in
this subgroup are needed. Gene-expression profiling
based on microarray analysis of 70 genes is a powerful
predictor for disease outcomes in patients with lymph-
node negative disease. [37] We demonstrate here in a lim-
ited number of patients that expression levels of a single
gene (IGF-I) can be used to independently predict the risk
of disease recurrence and death in lymph-negative
patients. Further studies evaluating this marker in a larger
cohort of patients are needed to determine its prognostic
and predictive potential.
Our results point to the hypothesis that both IGF-I and
SOCS2 expression in breast cancer is controlled by similar
mechanisms. A possible common signaling intermediate
could be STAT5, since both IGF-I and SOCS2 have been
described as STAT5 target genes [38,39]. STAT5 is essential
for mammary gland development and lactogenesis
[40,41], and alterations and repression in the signaling
cascade could result in less differentiated and more malig-
nant tumors. This is in line with recent findings showing
that breast lesions with aberrantly proliferating cells like
atypical ductal hyperplasia, ductal carcinoma in situ and
invasive carcinomas are characterized by a reduction or
absence of STAT5a expression [42]. Activation of STAT5,
as determined by tyrosine phosphorylation, decreases
during metastatic progression of breast cancer, and in a
large patient cohort, activated STAT5 emerged as an inde-
pendent prognostic marker for good prognosis in women
with breast cancer [43]. Furthermore, STAT5 expression
levels in the primary tumor as determined by immunohis-
tochemisty was associated with better response to endo-
crine therapy suggesting a possible crosstalk between ER
and STAT5, which could be mediated by SOCS2 [44].
Interestingly, CIS, another known STAT5 target gene, was
strongly correlated with SOCS2 and IGF-I, but did not
prove to be a prognostic marker.
Whereas SOCS2 was initially described as a negative regu-
lator of GH signaling [30], recent reports suggest that
depending on the expression level, SOCS2 can act as
either an enhancer or suppressor of this signaling pathway
[45,46]. SOCS2 knock out mice show only modest
increase in STAT5 phosphorylation [39] and overexpres-
sion of SOCS2 even results in an enhancement of GH sig-
naling in vivo and in vitro [46]. Therefore, high STAT5
activation in the tumor is compatible with higher SOCS2
levels. Interestingly, GH-transgenic mice lacking one copy
of SOCS2 show a high incidence in aberrant lesions in the
colon indicating that small variations of SOCS2 expres-
sion levels can have profound implications on cell prolif-
eration and eventually tumor growth [47].
In a comprehensive study Kate Sutherland et al. evaluated
promoter CpG island methylation and loss of heterozy-
gosity (LOH) of the SOCS1, SOCS2 and SOCS3 genes in
ovarian and breast cancer [8]. In 48 primary breast cancer
samples no methylation was observed and only 13% of
tumors showed LOH in the SOCS2 locus. Similar, unpub-
lished results from our group show no significant CpG
island methylation in SOCS2 locus in a limited number of
breast cancer samples (Haffner MC and Auer D, unpub-
lished data). In conclusion, the current data do not sup-
port methylation as a major factor contributing to
differences in SOCS2 expression levels in primary breast
cancers.
Our observation of higher SOCS2 expression levels in ER
positive tumors, raises the hypothesis that functional ER
signaling contributes to enhanced SOCS2 transcription.
This is in accordance with a recent report showing selec-
tive upregulation of SOCS2 expression by estrogen in
vitro [48]. In addition, mice carrying a targeted deletion of
the estrogen receptor failed to show an increased SOCS2
expression upon estrogen stimulation [49]. It still remains
to be shown whether high SOCS2 expression per se is
causative for the differences in tumor differentiation and
prolonged overall survival. Preliminary results from
MCF7 mammary carcinoma cells show that overexpres-
sion of SOCS2 results in a significant reduction of anchor-
age independent growth, which supports the hypothesis
of SOCS2 as an antioncogene [8]. Whether the favorable
prognostic characteristics of ER positive tumors can beBMC Cancer 2007, 7:136 http://www.biomedcentral.com/1471-2407/7/136
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attributed to some extent to higher SOCS2 expression
needs to be further clarified.
Conclusion
This is the first report on the prognostic significance of
SOCS2 expression in breast cancer. We further provide
new evidence that high expression of IGF-I is associated
with favorable prognosis especially in patients with
lymph-node negative disease. Taken together our findings
contribute to a better understanding of the function of
SOCS proteins and IGF-I expression in breast cancer. Fur-
thermore, if confirmed in larger studies, determination of
SOCS2 and IGF-I expression levels could be used in clini-
cal decision making for patients with breast cancer.
Abbreviations
CIS, cytokine-inducible SH2 containing protein; ER,
estrogen receptor; GH, growth hormone; HR, hazard
ratio; IGF-I, insulin-like growth factor 1; LN, lymph node;
PR, progesterone receptor; SOCS, suppressors of cytokine
signaling; STAT, signal transducer and activator of tran-
scription.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
MCH conceived the study, performed experiments and
wrote the paper. BP participated in RT-PCR analysis and
study design. JPP and FR contributed patients' samples
and clinical data. EM-H carried out the pathological stud-
ies. GD and CM contributed to study design and provided
samples. WD conceived and coordinated the study and
wrote the manuscript. All authors read and approved the
final manuscript.
Additional material
Acknowledgements
The authors want to thank Chiara Berlato for helpful discussion and inval-
uable comments on the manuscript, Anto Nogalo and Martina Chamson for 
excellent technical support and Petra Massoner and Helmut Klocker for 
kindly providing IGF-I primers. This project was supported by the Jubilae-
umsfonds of the Austrian National Bank, Project Nr.P10263, the Amadée 
program, and the Austrian Science Fund, project SFB021.
References
1. Alexander WS, Hilton DJ: The role of suppressors of cytokine
signaling (SOCS) proteins in regulation of the immune
response.  Annu Rev Immunol 2004, 22:503-529.
2. Ryo A, Suizu F, Yoshida Y, Perrem K, Liou YC, Wulf G, Rottapel R,
Yamaoka S, Lu KP: Regulation of NF-kappaB signaling by Pin1-
dependent prolyl isomerization and ubiquitin-mediated pro-
teolysis of p65/RelA.  Mol Cell 2003, 12(6):1413-1426.
3. Liu E, Cote JF, Vuori K: Negative regulation of FAK signaling by
SOCS proteins.  Embo J 2003, 22(19):5036-5046.
4. De Sepulveda P, Okkenhaug K, Rose JL, Hawley RG, Dubreuil P, Rot-
tapel R: Socs1 binds to multiple signalling proteins and sup-
presses steel factor-dependent proliferation.  Embo J 1999,
18(4):904-915.
5. Rui L, Yuan M, Frantz D, Shoelson S, White MF: SOCS-1 and
SOCS-3 block insulin signaling by ubiquitin-mediated degra-
dation of IRS1 and IRS2.  J Biol Chem 2002, 277(44):42394-42398.
6. De Sepulveda P, Ilangumaran S, Rottapel R: Suppressor of cytokine
signaling-1 inhibits VAV function through protein degrada-
tion.  J Biol Chem 2000, 275(19):14005-14008.
7. Oshimo Y, Kuraoka K, Nakayama H, Kitadai Y, Yoshida K, Chayama
K, Yasui W: Epigenetic inactivation of SOCS-1 by CpG island
hypermethylation in human gastric carcinoma.  Int J Cancer
2004, 112(6):1003-1009.
8. Sutherland KD, Lindeman GJ, Choong DY, Wittlin S, Brentzell L, Phil-
lips W, Campbell IG, Visvader JE: Differential hypermethylation
of SOCS genes in ovarian and breast carcinomas.  Oncogene
2004, 23(46):7726-7733.
9. Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Man-
ning JE, Harris CC, Herman JG: SOCS-1, a negative regulator of
the JAK/STAT pathway, is silenced by methylation in human
hepatocellular carcinoma and shows growth-suppression
activity.  Nat Genet 2001, 28(1):29-35.
10. Weber A, Hengge UR, Bardenheuer W, Tischoff I, Sommerer F,
Markwarth A, Dietz A, Wittekind C, Tannapfel A: SOCS-3 is fre-
quently methylated in head and neck squamous cell carci-
noma and its precursor lesions and causes growth inhibition.
Oncogene 2005, 24(44):6699-6708.
11. He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, Costello JF, McCor-
mick F, Jablons DM: SOCS-3 is frequently silenced by hyper-
methylation and suppresses cell growth in human lung
cancer.  Proc Natl Acad Sci U S A 2003, 100(24):14133-14138.
12. Watanabe D, Ezoe S, Fujimoto M, Kimura A, Saito Y, Nagai H,
Tachibana I, Matsumura I, Tanaka T, Kanegane H, Miyawaki T, Emi M,
K a n a k u r a  Y ,  K a w a s e  I ,  N a k a  T ,  K i s h i m o t o  T :  Suppressor of
cytokine signalling-1 gene silencing in acute myeloid leukae-
mia and human haematopoietic cell lines.  Br J Haematol 2004,
126(5):726-735.
13. Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG: SOCS-1, a
negative regulator of cytokine signaling, is frequently
silenced by methylation in multiple myeloma.  Blood 2003,
101(7):2784-2788.
14. Rottapel R, Ilangumaran S, Neale C, La Rose J, Ho JM, Nguyen MH,
Barber D, Dubreuil P, de Sepulveda P: The tumor suppressor
activity of SOCS-1.  Oncogene 2002, 21(28):4351-4362.
15. Pollak MN, Schernhammer ES, Hankinson SE: Insulin-like growth
factors and neoplasia.  Nat Rev Cancer 2004, 4(7):505-518.
16. Wood TL, Richert MM, Stull MA, Allar MA: The insulin-like
growth factors (IGFs) and IGF binding proteins in postnatal
development of murine mammary glands.  J Mammary Gland
Biol Neoplasia 2000, 5(1):31-42.
17. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE: The effects
of insulin-like growth factors on tumorigenesis and neoplas-
tic growth.  Endocr Rev 2000, 21(3):215-244.
18. Widschwendter A, Tonko-Geymayer S, Welte T, Daxenbichler G,
Marth C, Doppler W: Prognostic significance of signal trans-
ducer and activator of transcription 1 activation in breast
cancer.  Clin Cancer Res 2002, 8(10):3065-3074.
19. Marth C, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Doppler W,
Daxenbichler G: Interferon-gamma expression is an independ-
Additional file 1
Representative RT-PCR amplification plots. Representative real-time PCR 
amplification plots for SOCS2, IGF-I and TBP in primary mammary car-
cinoma samples. Each reaction included a standard-control sample and a 
non- template-control together with up to 45 patient samples. All reactions 
were performed in duplicates. Detected Ct-values ranged from 22.48 to 
30.81 for SOCS2, 23.8 to 31.87 for IGF-I and 22.0 to 26.72 for TBP.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-7-136-S1.eps]BMC Cancer 2007, 7:136 http://www.biomedcentral.com/1471-2407/7/136
Page 9 of 9
(page number not for citation purposes)
ent prognostic factor in ovarian cancer.  Am J Obstet Gynecol
2004, 191(5):1598-1605.
20. Bieche I, Onody P, Laurendeau I, Olivi M, Vidaud D, Lidereau R,
Vidaud M: Real-time reverse transcription-PCR assay for
future management of ERBB2-based clinical applications.
Clin Chem 1999, 45(8 Pt 1):1148-1156.
21. Masuhara M, Sakamoto H, Matsumoto A, Suzuki R, Yasukawa H, Mit-
sui K, Wakioka T, Tanimura S, Sasaki A, Misawa H, Yokouchi M, Oht-
subo M, Yoshimura A: Cloning and characterization of novel
CIS family genes.  Biochem Biophys Res Commun 1997,
239(2):439-446.
22. Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner
E, Deibl M, Gastl G, Gunsilius E, Marth C: The expression of the
regulatory T cell-specific forkhead box transcription factor
FoxP3 is associated with poor prognosis in ovarian cancer.
Clin Cancer Res 2005, 11(23):8326-8331.
23. Farabegoli F, Ceccarelli C, Santini D, Taffurelli M: Suppressor of
cytokine signalling 2 (SOCS-2) expression in breast carci-
noma.  J Clin Pathol 2005, 58(10):1046-1050.
24. Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D,
Wang D, Brown M, Bodner S, Grosveld G, Ihle JN: Stat5a and
Stat5b proteins have essential and nonessential, or redun-
dant, roles in cytokine responses.  Cell 1998, 93(5):841-850.
25. Shin A, Ren Z, Shu XO, Cai Q, Gao YT, Zheng W: Expression pat-
terns of insulin-like growth factor 1 (IGF-I) and its receptor
in mammary tissues and their associations with breast can-
cer survival.  Breast Cancer Res Treat 2006.
26. Rosen PP, Saigo PE, Braun DW, Weathers E, Kinne DW: Prognosis
in stage II (T1N1M0) breast cancer.  Ann Surg 1981,
194(5):576-584.
27. Hendriksen PJ, Dits NF, Kokame K, Veldhoven A, van Weerden WM,
Bangma CH, Trapman J, Jenster G: Evolution of the androgen
receptor pathway during progression of prostate cancer.
Cancer Res 2006, 66(10):5012-5020.
28. Wikman H, Kettunen E, Seppanen JK, Karjalainen A, Hollmen J, Ant-
tila S, Knuutila S: Identification of differentially expressed genes
in pulmonary adenocarcinoma by using cDNA array.  Onco-
gene 2002, 21(37):5804-5813.
29. Raccurt M, Tam SP, Lau P, Mertani HC, Lambert A, Garcia-Caballero
T, Li H, Brown RJ, McGuckin MA, Morel G, Waters MJ: Suppressor
of cytokine signalling gene expression is elevated in breast
carcinoma.  Br J Cancer 2003, 89(3):524-532.
30. Metcalf D, Greenhalgh CJ, Viney E, Willson TA, Starr R, Nicola NA,
Hilton DJ, Alexander WS: Gigantism in mice lacking suppressor
of cytokine signalling-2.  Nature 2000, 405(6790):1069-1073.
31. Greenhalgh CJ, Rico-Bautista E, Lorentzon M, Thaus AL, Morgan PO,
Willson TA, Zervoudakis P, Metcalf D, Street I, Nicola NA, Nash AD,
Fabri LJ, Norstedt G, Ohlsson C, Flores-Morales A, Alexander WS,
Hilton DJ: SOCS2 negatively regulates growth hormone
action in vitro and in vivo.  J Clin Invest 2005, 115(2):397-406.
32. Hadsell DL, Murphy KL, Bonnette SG, Reece N, Laucirica R, Rosen
JM: Cooperative interaction between mutant p53 and des(1-
3)IGF-I accelerates mammary tumorigenesis.  Oncogene 2000,
19(7):889-898.
33. Wu Y, Cui K, Miyoshi K, Hennighausen L, Green JE, Setser J, LeRoith
D, Yakar S: Reduced circulating insulin-like growth factor I
levels delay the onset of chemically and genetically induced
mammary tumors.  Cancer Res 2003, 63(15):4384-4388.
34. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS,
Deroo B, Rosner B, Speizer FE, Pollak M: Circulating concentra-
tions of insulin-like growth factor-I and risk of breast cancer.
Lancet 1998, 351(9113):1393-1396.
35. Voskuil DW, Bosma A, Vrieling A, Rookus MA, van 't Veer LJ: Insu-
lin-like growth factor (IGF)-system mRNA quantities in nor-
mal and tumor breast tissue of women with sporadic and
familial breast cancer risk.  Breast Cancer Res Treat 2004,
84(3):225-233.
36. Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ, Lippman
ME, Rosen N: Analysis of insulin-like growth factor I gene
expression in malignancy: evidence for a paracrine role in
human breast cancer.  Mol Endocrinol 1989, 3(3):509-517.
37. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW,
Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D,
Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H,
Rodenhuis S, Rutgers ET, Friend SH, Bernards R: A gene-expres-
sion signature as a predictor of survival in breast cancer.  N
Engl J Med 2002, 347(25):1999-2009.
38. Davey HW, Xie T, McLachlan MJ, Wilkins RJ, Waxman DJ, Grattan
DR:  STAT5b is required for GH-induced liver IGF-I gene
expression.  Endocrinology 2001, 142(9):3836-3841.
39. Greenhalgh CJ, Bertolino P, Asa SL, Metcalf D, Corbin JE, Adams TE,
Davey HW, Nicola NA, Hilton DJ, Alexander WS: Growth
enhancement in suppressor of cytokine signaling 2 (SOCS-
2)-deficient mice is dependent on signal transducer and acti-
vator of transcription 5b (STAT5b).  Mol Endocrinol 2002,
16(6):1394-1406.
40. Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A,
Hennighausen L: Stat5a is mandatory for adult mammary
gland development and lactogenesis.  Genes Dev 1997,
11(2):179-186.
41. Cui Y, Riedlinger G, Miyoshi K, Tang W, Li C, Deng CX, Robinson
GW, Hennighausen L: Inactivation of Stat5 in mouse mammary
epithelium during pregnancy reveals distinct functions in cell
proliferation, survival, and differentiation.  Mol Cell Biol 2004,
24(18):8037-8047.
42. Bratthauer GL, Strauss BL, Tavassoli FA: STAT 5a expression in
various lesions of the breast.  Virchows Arch 2006,
448(2):165-171.
43. Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Kononen J,
Sauter G, Rui H: Signal transducer and activator of transcrip-
tion-5 activation and breast cancer prognosis.  J Clin Oncol
2004, 22(11):2053-2060.
44. Yamashita H, Nishio M, Ando Y, Zhang Z, Hamaguchi M, Mita K,
Kobayashi S, Fujii Y, Iwase H: Stat5 expression predicts response
to endocrine therapy and improves survival in estrogen
receptor-positive breast cancer.  Endocr Relat Cancer 2006,
13(3):885-893.
45. Favre H, Benhamou A, Finidori J, Kelly PA, Edery M: Dual effects of
suppressor of cytokine signaling (SOCS-2) on growth hor-
mone signal transduction.  FEBS Lett 1999, 453(1-2):63-66.
46. Greenhalgh CJ, Metcalf D, Thaus AL, Corbin JE, Uren R, Morgan PO,
Fabri LJ, Zhang JG, Martin HM, Willson TA, Billestrup N, Nicola NA,
Baca M, Alexander WS, Hilton DJ: Biological evidence that
SOCS-2 can act either as an enhancer or suppressor of
growth hormone signaling.  J Biol Chem 2002,
277(43):40181-40184.
47. Michaylira CZ, Ramocki NM, Simmons JG, Tanner CK, McNaughton
KK, Woosley JT, Greenhalgh CJ, Lund PK: Haplotype insufficiency
for suppressor of cytokine signaling-2 enhances intestinal
growth and promotes polyp formation in growth hormone-
transgenic mice.  Endocrinology 2006, 147(4):1632-1641.
48. Leung KC, Doyle N, Ballesteros M, Sjogren K, Watts CK, Low TH,
Leong GM, Ross RJ, Ho KK: Estrogen inhibits GH signaling by
suppressing GH-induced JAK2 phosphorylation, an effect
mediated by SOCS-2.  Proc Natl Acad Sci U S A 2003,
100(3):1016-1021.
49. Leong GM, Moverare S, Brce J, Doyle N, Sjogren K, Dahlman-Wright
K, Gustafsson JA, Ho KK, Ohlsson C, Leung KC: Estrogen up-reg-
ulates hepatic expression of suppressors of cytokine signal-
ing-2 and -3 in vivo and in vitro.  Endocrinology 2004,
145(12):5525-5531.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/7/136/pre
pub